

# **Donepezil Drug Use Criteria**

Created: September 2011 Reviewed: 4/22/2019

Includes:

Aricept© Donepezil

## **GUIDELINE FOR USE**:

- 1. Is the patient being treated for dementia of the Alzheimer's type?
  - a. If yes, go to 2
  - b. If no, deny as not meeting criteria. Donepezil is an FDA approved for treatment of mild, moderate and severe dementia of the Alzheimer's type.
- 2. Is the requested dosing consistent with the FDA approved prescribing information for the patient's disease severity?
  - a. If yes, go to 3
  - b. If no, deny as not meeting criteria. Off label use of medication is not a covered benefit on OHP.
- 3. Does the patient have any contraindications to donepezil therapy?
  - a. If yes, deny as not meeting criteria. Medication should be prescribed consistent with the FDA package insert.
  - b. If no, approve for 12 fills.

## **Rationale:**

To promote the use of donepezil for FDA approved indications and dose consistent with the FDA approved prescribing information.

## FDA Approved Indications:

Donepezil is indicated for the treatment of mild, moderate and severe dementia of the Alzheimer's type.

#### **Mechanism of Action:**

Donepezil is an acetylcholinesterase inhibitor indicated for the treatment of dementia of the Alzheimer's type.

## Dosing:

Mild to moderate Alzheimer's disease: 5 to 10 mg once daily Moderate to severe Alzheimer's disease: 10 to 23 mg once daily

### **Contraindications:**

Known hypersensitivity to donepezil or to piperidine derivatives

## **References:**

1. Aricept© (Donepezil) prescribing information. Revised 12/2018

Approved by Advanced Health Pharmacy and Therapeutics Committee 4/22/2019